News

TAK-875 is a selective agonist of GPR40, one of the G-protein-coupled receptors that are expressed in pancreatic islet cells. The first double-blind, randomized, 24-week Phase 3 trial in

The G4 platform provides an intuitive user interface across the products and a single unified database across automated medication dispensing cabinets which aid in decreasing the risk of

The proteomic technology will be applied to biomarker discovery, target discovery and validation, and companion diagnostics. SomaLogic CEO Larry Gold said their technology would help address the issues

The infections include Complicated Intra-Abdominal Infections (cIAI) and Complicated Urinary Tract Infections (cUTI). CAZ-AVI comprises cephalosporin (ceftazidime) and a novel beta-lactamase inhibitor (avibactam), which helps overcome antibiotic-resistance and

PromoMats will enable life sciences companies to manage promotional material life cycle including concept and strategy, association of claims and reference documents, besides medical, legal and regulatory review.

MGCD290 is an oral Hos2 fungal inhibitor and was designed to be co-administered with azoles like fluconazole in order to enhance activity against fungal infections. The Phase 2

UshStat utilizes the company’s LentiVector platform technology to deliver a corrected version of the MYO7A gene to address the vision loss associated with the disease. The Phase I/IIa

HannaH, an open-label trial involving 596 women compared Herceptin given as subcutaneous (SC) injection versus that given as an intravenous (IV) infusion. Herceptin SC uses Enhanze Technology which

Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells which help in immunity, as well as kinases that play key roles in various cancers. The